[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dr. Md. Alimur Reza\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100600611","effectiveness-and-safety-of-tirzepatide-among-participants-with-obesity-with-or-without-type-2-diabetes-mellitus-t2dm-100600611",false,"NCT07099742","Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)","A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh","Inclusion Criteria:\n\n* Adult patients of both sexes, aged ≥18 years.\n* Body mass index (BMI) ≥25 kg\u002Fm².\n* Naïve to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.\n* Self-reported stable body weight (change ≤5 kg) over the past 3 months.\n\nExclusion Criteria:\n\n* Diagnosis of diabetes other than Type 2 Diabetes Mellitus.\n* History of chronic or acute pancreatitis.\n* Presence of acute medical conditions, including acute hepatitis, myocardial infarction, stroke, heart failure, febrile illness, or acute diarrheal disease.\n* Evidence of significant, uncontrolled endocrine disorders (e.g., Cushing's syndrome, thyroid disorders, adrenal insufficiency, congenital adrenal hyperplasia).\n* History or presence of malignancy.\n* Active gallbladder disease.\n* Female participants who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential, not using adequate contraceptive methods.\n* Prior or planned surgical treatment for obesity.\n* Use of weight-loss products (including prescription medications, over-the-counter drugs, or herbal preparations) within 3 months prior to screening.","ALL","18 Years",{"count":19,"type":20},364,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM).\n\nThe study aims to determine whether treatment with Tirzepatide results in superior weight reduction outcomes compared to lifestyle-based approaches. Adult participants (≥18 years) with a body mass index (BMI) ≥25 kg\u002Fm² and no prior exposure to GLP-1 receptor agonists will be enrolled at the discretion of the treating physician. Eligible participants will receive either once-weekly Tirzepatide or participate in lifestyle intervention programs aligned with standard clinical care.",[24],"Obesity",[26,24,27],"Tirzepatide","T2DM","NOT_YET_RECRUITING","2025-07-31",{"date":31,"type":32},"2025-08-03","ACTUAL",{"date":34,"type":20},"2025-09",{"date":36,"type":20},"2026-07",{"name":38,"class":39},"Dr. Md. Alimur Reza","INDUSTRY",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100576756","phase-4-efficacy-and-safety-of-atorvastatin-and-ezetimibe-1010mg-fixed-dose-combination-versus-atorvastatin-20mg-monotherapy-in-bangladeshi-population-100576756","NCT06789432","Efficacy and Safety of Atorvastatin and Ezetimibe (10\u002F10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population","Inclusion Criteria:\n\n* Men and women aged \\>18 years.\n* Patients with a confirmed diagnosis of elevated LDL-C levels necessitating medical management.\n* Patients in the low to moderate cardiovascular disease (CVD) risk category according to ESC guidelines (2019)\n\n  * Low-risk: Increased LDL-C level without any co-morbidities\n  * Moderate-risk: Young patients (T1DM \\\u003C35 years; T2DM \\\u003C50 years) with DM duration \\\u003C10 years, without other risk factors.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any study drugs.\n* Clinically significant hepatic impairment (ALT, AST level \\> 2xULN) and\u002For renal impairment (Serum creatinine level ≥2xULN).\n* Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, cancer, psychiatric instability, HIV + status, intestinal malabsorption.\n* Pregnant or lactating females.\n* The presence of a condition that, in the opinion of the investigator, would place the subject at increased risk from study participation.",{"count":48,"type":20},500,"INTERVENTIONAL",[51],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the Bangladeshi population.\n\nResearchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) FDC works to treat dyslipidemia.\n\nParticipants will:\n\n* Take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months\n* Follow-up visits at 6 weeks and 12 weeks for checkups and tests",[54],"Hyperlipidemia (E.G., Hypercholesterolemia)",[56,57,58],"increased LDL-C level","Hyperlipidemia","Atorvastatin (10 mg) and Ezetimibe (10 mg)","RECRUITING","2025-07-25",{"date":62,"type":32},"2025-07-29",{"date":64,"type":32},"2025-02-01",{"date":66,"type":20},"2025-12",{"name":38,"class":39},1,""]